- Spain CIMA (Spanish): search for “roxitromicin” (external search; text not reproduced)
External search; text not reproduced. Check the Philippine package insert in the products table.
Contraindications
- Macrolide hypersensitivity
- Severely impaired hepatic function
- Ergot alkaloids
Dosing: Adult
- Respiratory, ENT, skin and genital infections (adults): 300 mg once daily or 150 mg twice daily for 5 to 10 days
- Severe hepatic insufficiency or cirrhosis: 150 mg once daily
Dosing: Altered kidney function
Roxithromycin is a macrolide eliminated mainly in feces (about 7% in urine). Its half-life lengthens from about 12 to 18 hours in kidney insufficiency, but the New Zealand data sheet does not require a dose reduction for the usual short course. Dose is halved in severe liver disease. It has no US FDA label.
Kidney function measure: The data sheet does not grade kidney impairment; bands shown on creatinine clearance (CrCl).
Show full dosing details
- CrCl ≥60 mL/min
- Usual: 300 mg/day (300 mg once daily or 150 mg twice daily) for 5 to 10 days; at least 10 days for streptococcal throat infection (data sheet).
- CrCl 30–59 mL/min
- No dose reduction needed for the usual short course; half-life about 18 hours in kidney insufficiency vs 12 hours in young adults (data sheet). About 7% of a dose is excreted in urine.
- CrCl 15–29 mL/min
- No dose reduction needed for the usual short course; half-life about 18 hours in kidney insufficiency vs 12 hours in young adults (data sheet). About 7% of a dose is excreted in urine.
- CrCl <15 mL/min (not on dialysis)
- No dose reduction needed for the usual short course; half-life about 18 hours in kidney insufficiency vs 12 hours in young adults (data sheet). About 7% of a dose is excreted in urine.
- Hemodialysis (intermittent)
- Dialysis not mentioned in the data sheet. Little renal elimination; no change expected for a short course.
- Peritoneal dialysis
- No change for a short course; not removed by CAPD (half-life about 21 hours; Lam 1995).
- CRRT
- Not mentioned.
- Dialyzable? Not stated (92% to 96% protein-bound).
- Monitoring QT risk factors (electrolyte disturbance common in kidney failure, bradycardia, QT drugs); INR with warfarin; digoxin levels and ECG (data sheet). Macrolide class warning: rare short-term risk of arrhythmia, myocardial infarction and cardiovascular death (data sheet 2025).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual weight-based dose (data sheet).
- eGFR 30–59
- No pediatric kidney data; adult data suggest no change for short courses.
- eGFR 15–29
- No pediatric kidney data; adult data suggest no change for short courses.
- eGFR <15 (not on dialysis)
- No pediatric kidney data; adult data suggest no change for short courses.
- Hemodialysis (intermittent)
- No pediatric data.
- Peritoneal dialysis
- No pediatric data.
- CRRT
- No pediatric data.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: Medsafe (New Zealand) product information (November 3, 2025). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Children (150 mg tablet only) (data sheet).
- Usual dose
- Children 40 kg and over: 150 mg twice daily (tablet data sheet). The data sheet gives no mg/kg dose for smaller children.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Film-coated tablet: 150 mg
Registered products in the Philippines
4 products registered with the Food and Drug Administration (FDA) Philippines list Roxithromycin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products4
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
PulvidRoxithromycin | 150 mg Film-Coated TabletStrip Foil x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Eadriex Pharmaceuticals, Phils., Inc. | DR-XY33267 | May 4, 2027 | |
Roxi-MRoxithromycin | 150 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | ZIM LABORATORIES LTD.India | DIAFARM INC.Trader: RAINBOW LIFE SCIENCES PVT. LTD. | DRP-4171 | Jan 3, 2028 | |
RoxisaphRoxithromycin | 150 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's) | Rx | SAPPHIRE LIFESCIENCES PVT. LTDIndia | NELPA LIFESCIENCES, INC. | DRP-8381 | Sep 18, 2028 | |
RoxithinRoxithromycin | 150 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Brawn Laboratories LimitedIndia | Ambica International Corporation | DRP-4488 | Jun 18, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Ergotamine, dihydroergotamine | Avoid | Ergotism. | Contraindicated. |
| Terfenadine, astemizole, cisapride, pimozide | Avoid | QT prolongation. | Not recommended. |
| Class IA and III antiarrhythmics, disopyramide | Adjust or monitor | QT prolongation; higher disopyramide levels. | Use with caution; ECG. |
| Warfarin | Adjust or monitor | INR rise; severe bleeding reported. | Monitor INR. |
| Digoxin | Adjust or monitor | Higher digoxin levels. | Monitor ECG and levels. |
| Midazolam, theophylline, cyclosporine, rifabutin, bromocriptine | Minor | Modest rises (weak CYP3A4 inhibition). | Monitor. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Nausea, vomiting, diarrhea, abdominal pain
Serious
- QT prolongation, torsades de pointes
- Stevens-Johnson syndrome, toxic epidermal necrolysis
- Hepatitis (raised transaminases)
Monitoring parameters
- QT risk factors (electrolyte disturbance common in kidney failure, bradycardia, QT drugs); INR with warfarin; digoxin levels and ECG (data sheet). Macrolide class warning: rare short-term risk of arrhythmia, myocardial infarction and cardiovascular death (data sheet 2025). Kidney
- QT risk factors
- INR with warfarin
Pharmacokinetics
Key PK parameters
| Bioavailability | About 50% |
|---|---|
| Half-life | About 12 hours (young adults); 20 hours in children; 27 hours in older adults |
| Half-life in kidney failure (ESKD) kidney | About 18 hours in kidney insufficiency |
| Protein binding | 92% to 96% (alpha-1-acid glycoprotein) |
| Renal excretion kidney | About 7% in urine; 53% in feces; 13% via lungs |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Medsafe (New Zealand Medicines and Medical Devices Safety Authority). Arrow-Roxithromycin tablets data sheet [Medsafe (New Zealand) product information, November 3, 2025; no US FDA label]. https://www.medsafe.govt.nz/Profs/datasheet/a/ArrowRoxithromycintab.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Teva Pharma (New Zealand) Limited. (2025). Arrow-Roxithromycin 150 mg and 300 mg tablets [New Zealand data sheet; revised November 3, 2025]. Medsafe, New Zealand Medicines and Medical Devices Safety Authority. https://www.medsafe.govt.nz/Profs/datasheet/a/ArrowRoxithromycintab.pdf
- Lam, Y. W., Flaherty, J. F., Yumena, L., Schoenfeld, P. Y., & Gambertoglio, J. G. (1995). Roxithromycin disposition in patients on continuous ambulatory peritoneal dialysis. Journal of Antimicrobial Chemotherapy, 36(1), 157–163. https://doi.org/10.1093/jac/36.1.157
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .